Journal Article

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

Wang, Jian, Zhong, Chenhan, Hu, Hanguang, Xiao, Qian, Xu, Dong, Wang, Jianwei, Ding, Kefeng, Liao, Xiujun, Li, Jun, Weng, Shanshan, Sun, Lifeng, Dong, Caixia, Yuan, Ying, Zhang, Suzhan, Fang, Xuefeng

2023

Overview

Background Rat sarcoma viral oncogene homolog (RAS) gene mutation is a common molecular event in colorectal cancer (CRC). The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8–9 months. Immunotherapy, especially anti-programmed death 1 (PD-1) monoclonal antibody has demonstrated ground-breaking results in deficient mismatch repair (dMMR) / microsatellite instability-high (MSI-H) mCRC patients. However, the response rate of in microsatellite stable (MSS) patients is extremely low. In addition, preclinical studies have demonstrated that anti - Vascular endothelial growth factor (VEGF) agents, such as bevacizumab, can induce tumor vascular normalization and enhance antitumor immunity. Previous study indicated the combination of chemotherapy, anti-VEGF agents (bevacizumab) with immune checkpoint inhibitors may have promising clinical activity in RAS mutant, MSS refractory mCRC patients. Based on these evidences, we will explore the combination of CapeOx with bevacizumab and sintilimab (anti-PD-1 monoclonal antibody) in RAS mutant, MSS mCRC patients as first-line therapy. Methods This is a randomized, open-label, multicentric clinical trial. In the sintilimab arm, patients will receive sintilimab in combination with CapeOx and bevacizumab. In the control arm, patients will receive CapeOx and bevacizumab. This trial will recruit 494 patients from 20 centers and randomly (1:1) disseminated into two groups. The primary endpoint is the PFS. The secondary endpoints include overall survival, safety, ORR, and disease control rate. Discussion This study may provide new ideas for optimizing oncology treatment planning for RAS mutant, MSS mCRC patients in the first-line set. Trial registration This study is short for BBCAPX and has been registered at clinicaltrials.gov registry with identifier NCT05171660.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Bevacizumab / Biomedical and Life Sciences / Biomedicine / Cancer Research / Cancer therapies / CapeOx / Care and treatment / Chemotherapy / Clinical trials / Colorectal cancer / Colorectal carcinoma / Diagnosis / Disease control / Dosage and administration / Drug dosages / FDA approval / First line therapy / Gene mutations / Health aspects / Health Promotion and Disease Prevention / Immune checkpoint inhibitors / Immunotherapy / Induction therapy / Medical prognosis / Medicine/Public Health / Metastases / Metastasis / Metastatic colorectal cancer / Microsatellite instability / Mismatch repair / Monoclonal antibodies / Mutants / Mutation / Oncology / Oxaliplatin / Patient outcomes / Patients / PD-1 protein / Point mutation / RAS-mutant / Response rates / Sarcoma / Sintilimab / Study Protocol / Surgical Oncology / Survival / Targeted cancer therapy / Tumors / Vascular endothelial growth factor